U.S. markets close in 3 hours 29 minutes
  • S&P 500

    3,638.45
    -2.02 (-0.06%)
     
  • Dow 30

    29,102.93
    -122.68 (-0.42%)
     
  • Nasdaq

    10,769.10
    +31.59 (+0.29%)
     
  • Russell 2000

    1,695.70
    +20.76 (+1.24%)
     
  • Crude Oil

    80.24
    -0.99 (-1.22%)
     
  • Gold

    1,674.80
    +6.20 (+0.37%)
     
  • Silver

    19.11
    +0.40 (+2.15%)
     
  • EUR/USD

    0.9785
    -0.0035 (-0.35%)
     
  • 10-Yr Bond

    3.7440
    -0.0030 (-0.08%)
     
  • GBP/USD

    1.1112
    -0.0011 (-0.10%)
     
  • USD/JPY

    144.7350
    +0.2920 (+0.20%)
     
  • BTC-USD

    19,693.77
    +512.56 (+2.67%)
     
  • CMC Crypto 200

    449.81
    +6.38 (+1.44%)
     
  • FTSE 100

    6,893.81
    +12.22 (+0.18%)
     
  • Nikkei 225

    25,937.21
    -484.84 (-1.83%)
     

UK's NICE Recommends BeiGene's Cancer Drug For Rare Form Of Blood Cancer

·1 min read
  • England's National Institute for Health and Care Excellence (NICE) has recommended BeiGene Ltd's (NASDAQ: BGNE) Brukinsa (zanubrutinib) for Waldenström's Macroglobulinemia (WM) in adults who have had at least one treatment, only if bendamustine plus rituximab is also suitable.

  • This decision from NICE marks Brukinsa as the first and only treatment for WM to be recommended for routine use in England and Wales.

  • Also Read: BeiGene's Brukinsa Tops JNJ's Imbruvica In Overall Response Rate In Leukemia Study.

  • WM is a rare form of B-cell lymphoma that occurs in less than two percent of patients with non-Hodgkin lymphomas. Around 4,000 people are living with WM in the U.K.

  • The NICE recommendation states that Brukinsa is considered cost-effective at a threshold of £20,000-30,000 per quality-adjusted life year.

  • Also, the European Medicines Agency's Committee for Medicinal Products for Human Use backed Brukinsa approval for marginal zone lymphoma patients who have received at least one prior anti-CD20-based therapy.

  • Price Action: BGNE shares closed lower by 1.45% at $154.82 on Monday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.